BE1022355A1 - Nouvelles méthodes d'induction d'une réponse immunitaire - Google Patents

Nouvelles méthodes d'induction d'une réponse immunitaire Download PDF

Info

Publication number: BE1022355A1
Authority: BE; Belgium
Prior art keywords: induction; immune response; new methods; new; methods
Prior art date: 2014-04-02

Application number

BE201505209A

Other languages

English (en)

Other versions

BE1022355B1 (fr

Inventor

William Ripley Ballou Jr

Arnaud Michel Didierlaurent

Der Most Robbert Gerrit Van

Original Assignee

Glaxosmithkline Biologicals Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-02

Filing date

2015-04-02

Publication date

2016-02-16

2015-04-02 Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa

2016-02-16 Publication of BE1022355A1 publication Critical patent/BE1022355A1/fr

2016-03-26 Application granted granted Critical

2016-03-26 Publication of BE1022355B1 publication Critical patent/BE1022355B1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Tropical Medicine & Parasitology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BE2015/5209A 2014-04-02 2015-04-02 Nouvelles méthodes d'induction d'une réponse immunitaire BE1022355B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1405921.6A GB201405921D0 (en)	2014-04-02	2014-04-02	Novel methods for inducing an immune response
GB1405921.6		2014-04-02

Publications (2)

Publication Number	Publication Date
BE1022355A1 true BE1022355A1 (fr)	2016-02-16
BE1022355B1 BE1022355B1 (fr)	2016-03-26

Family

ID=50737873

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2015/5209A BE1022355B1 (fr)	2014-04-02	2015-04-02	Nouvelles méthodes d'induction d'une réponse immunitaire

Country Status (18)

Country	Link
US (3)	US10624961B2 (fr)
EP (2)	EP3125930B1 (fr)
JP (2)	JP6645982B2 (fr)
KR (2)	KR102762440B1 (fr)
CN (2)	CN106456738B (fr)
AR (1)	AR099960A1 (fr)
AU (1)	AU2015239025B2 (fr)
BE (1)	BE1022355B1 (fr)
BR (2)	BR112016022463A2 (fr)
CA (2)	CA2943007C (fr)
EA (1)	EA037405B1 (fr)
ES (2)	ES2961840T3 (fr)
GB (1)	GB201405921D0 (fr)
IL (1)	IL247493B (fr)
MX (3)	MX2016012932A (fr)
SG (1)	SG11201607086QA (fr)
WO (2)	WO2015150567A1 (fr)
ZA (1)	ZA201605955B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201405921D0 (en) *	2014-04-02	2014-05-14	Glaxosmithkline Biolog Sa	Novel methods for inducing an immune response
GB201621686D0 (en) *	2016-12-20	2017-02-01	Glaxosmithkline Biologicals Sa	Novel methods for inducing an immune response
EP3630176A1 (fr)	2017-05-30	2020-04-08	GlaxoSmithKline Biologicals S.A.	Procédés de fabrication d'un adjuvant
EP3717001A1 (fr)	2017-12-01	2020-10-07	GlaxoSmithKline Biologicals S.A.	Purification de saponine
US20220235095A1 (en)	2019-06-05	2022-07-28	Glaxosmithkline Biologicals Sa	Saponin purification
CN113125756B (zh) *	2020-07-15	2022-10-25	南京岚煜生物科技有限公司	抗体标准品赋值和抗原中和当量确定的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US152200A (en) *		1874-06-16		Improvement in garters
US1002607A (en) *	1905-08-28	1911-09-05	John Willard Taylor	Paper pulley.
UA56132C2 (uk) *	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP1569515A4 (fr)	2002-10-23	2006-04-26	Glaxosmithkline Biolog Sa	Methodes de vaccination contre le paludisme
SI1802336T1 (sl)	2004-10-14	2012-01-31	Crucell Holland Bv	Začetna/obnovitvena cepiva proti malariji
HRP20120331T1 (hr) *	2005-04-29	2012-05-31	Glaxosmithkline Biologicals Sa	Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis
TWI457133B (zh) *	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
CA2668100C (fr) *	2006-11-01	2014-12-23	Immport Therapeutics, Inc.	Composition et procedes pour des antigenes immunodominants
AU2008223951B2 (en) *	2007-03-02	2014-03-27	Glaxosmithkline Biologicals S.A.	Novel method and compositions
AR066405A1 (es) *	2007-04-20	2009-08-19	Glaxosmithkline Biolog Sa	Vacuna
LT2315773T (lt) *	2008-07-25	2016-11-10	Glaxosmithkline Biologicals S.A.	Polipeptidai, polinukleotidai ir kompozicijos, skirti naudoti latentinės tuberkuliozės gydymui
EP2315597B1 (fr) *	2008-07-25	2017-08-23	GlaxoSmithKline Biologicals S.A.	Nouvelles compositions et procédés
PL2315834T3 (pl) *	2008-07-25	2018-12-31	Glaxosmithkline Biologicals S.A.	Białko rv2386c związane z gruźlicą, jego kompozycje i zastosowania
CN102869372B (zh) *	2010-01-27	2016-01-20	葛兰素史密丝克莱恩生物有限公司	经修饰的结核抗原
AU2011343367B2 (en) *	2010-12-14	2015-05-21	Glaxosmithkline Biologicals S.A.	Mycobacterium antigenic composition
US20170056345A1 (en) *	2014-02-18	2017-03-02	Stc.Unm	Booster drug therapy for mycobacterium infections
GB201405921D0 (en) *	2014-04-02	2014-05-14	Glaxosmithkline Biolog Sa	Novel methods for inducing an immune response
US10004793B2 (en) *	2014-04-24	2018-06-26	Statens Serum Institut	M.tuberculosis vaccines
GB201513176D0 (en) *	2015-07-27	2015-09-09	Glaxosmithkline Biolog Sa	Novel methods for inducing an immune response

2014
- 2014-04-02 GB GBGB1405921.6A patent/GB201405921D0/en not_active Ceased
2015
- 2015-04-02 MX MX2016012932A patent/MX2016012932A/es unknown
- 2015-04-02 WO PCT/EP2015/057423 patent/WO2015150567A1/fr not_active Ceased
- 2015-04-02 BE BE2015/5209A patent/BE1022355B1/fr not_active IP Right Cessation
- 2015-04-02 US US15/300,338 patent/US10624961B2/en active Active
- 2015-04-02 AU AU2015239025A patent/AU2015239025B2/en active Active
- 2015-04-02 CN CN201580016665.4A patent/CN106456738B/zh active Active
- 2015-04-02 KR KR1020237017095A patent/KR102762440B1/ko active Active
- 2015-04-02 BR BR112016022463A patent/BR112016022463A2/pt not_active Application Discontinuation
- 2015-04-02 EA EA201691638A patent/EA037405B1/ru not_active IP Right Cessation
- 2015-04-02 JP JP2016559965A patent/JP6645982B2/ja active Active
- 2015-04-02 EP EP15713531.0A patent/EP3125930B1/fr active Active
- 2015-04-02 CA CA2943007A patent/CA2943007C/fr active Active
- 2015-04-02 ES ES15713532T patent/ES2961840T3/es active Active
- 2015-04-02 SG SG11201607086QA patent/SG11201607086QA/en unknown
- 2015-04-02 MX MX2016012982A patent/MX2016012982A/es unknown
- 2015-04-02 JP JP2016560336A patent/JP6655549B2/ja not_active Expired - Fee Related
- 2015-04-02 CN CN201580030331.2A patent/CN106456739A/zh active Pending
- 2015-04-02 BR BR112016022787-5A patent/BR112016022787A2/pt not_active Application Discontinuation
- 2015-04-02 WO PCT/EP2015/057424 patent/WO2015150568A1/fr not_active Ceased
- 2015-04-02 KR KR1020167029523A patent/KR20160132115A/ko not_active Ceased
- 2015-04-02 ES ES15713531T patent/ES2853773T3/es active Active
- 2015-04-02 IL IL247493A patent/IL247493B/en unknown
- 2015-04-02 EP EP15713532.8A patent/EP3125929B8/fr active Active
- 2015-04-02 CA CA2943711A patent/CA2943711A1/fr not_active Abandoned
- 2015-04-02 US US15/300,852 patent/US10688168B2/en active Active
- 2015-04-06 AR ARP150101025A patent/AR099960A1/es unknown
2016
- 2016-08-26 ZA ZA2016/05955A patent/ZA201605955B/en unknown
- 2016-09-30 MX MX2022013912A patent/MX2022013912A/es unknown
2020
- 2020-03-11 US US16/815,635 patent/US11951161B2/en active Active

Also Published As

Publication number	Publication date
EP3125929B1 (fr)	2023-11-01
EA037405B1 (ru)	2021-03-25
WO2015150568A1 (fr)	2015-10-08
ES2853773T3 (es)	2021-09-17
BE1022355B1 (fr)	2016-03-26
CN106456738A (zh)	2017-02-22
CA2943007A1 (fr)	2015-10-08
ES2961840T3 (es)	2024-03-14
EP3125929A1 (fr)	2017-02-08
AU2015239025B2 (en)	2018-01-25
US11951161B2 (en)	2024-04-09
KR102762440B1 (ko)	2025-02-03
CN106456738B (zh)	2021-06-29
IL247493B (en)	2022-08-01
EP3125930B1 (fr)	2020-12-02
IL247493A0 (en)	2016-11-30
JP2017511324A (ja)	2017-04-20
US20200306353A1 (en)	2020-10-01
GB201405921D0 (en)	2014-05-14
JP2017511327A (ja)	2017-04-20
US20170136110A1 (en)	2017-05-18
EP3125929B8 (fr)	2023-12-27
JP6655549B2 (ja)	2020-02-26
SG11201607086QA (en)	2016-09-29
BR112016022787A2 (pt)	2018-03-27
EP3125929C0 (fr)	2023-11-01
CA2943711A1 (fr)	2015-10-08
US20170112914A1 (en)	2017-04-27
AU2015239025A1 (en)	2016-09-22
CN106456739A (zh)	2017-02-22
EP3125930A1 (fr)	2017-02-08
ZA201605955B (en)	2019-04-24
EA201691638A1 (ru)	2017-04-28
AR099960A1 (es)	2016-08-31
US10688168B2 (en)	2020-06-23
US10624961B2 (en)	2020-04-21
WO2015150567A1 (fr)	2015-10-08
KR20160132115A (ko)	2016-11-16
BR112016022463A2 (pt)	2017-10-10
MX2016012982A (es)	2016-12-07
MX2022013912A (es)	2022-12-13
CA2943007C (fr)	2024-01-09
MX2016012932A (es)	2016-12-07
KR20230075525A (ko)	2023-05-31
JP6645982B2 (ja)	2020-02-14

Publication	Publication Date	Title
EP3507298A4 (fr)	2021-03-10	Détection d'un carcinome hépatocellulaire
EP3405587A4 (fr)	2019-10-30	Méthodes pour induire une réponse immunitaire en activant la lecture de codons stop prématurés
EP4015535C0 (fr)	2025-08-06	Modification de la glyco-ingéniérie de fractions de ciblage spécifique à un site
EP3436083A4 (fr)	2019-11-27	Nouvelles compositions et méthodes
EP3099440C0 (fr)	2025-07-30	Atomisation centrifuge d'alliages à base de fer
MA49715A (fr)	2019-10-09	Oligomères et conjugués d'oligomères
EP3314503A4 (fr)	2019-05-08	Simulation d'une application
FR3026331B1 (fr)	2016-11-11	Douille d'extraction
EP3273950A4 (fr)	2019-04-24	Compositions adjuvantes et méthodes associées
SMT202400497T1 (it)	2025-01-14	Farmacoforo per induzione di trail
FI20145100L (fi)	2015-07-31	Magneetti
DK3534735T3 (da)	2022-08-08	En beklædningsgenstand
EP3436467A4 (fr)	2020-03-18	Nouvelles compositions et méthodes thérapeutiques
PT3092003T (pt)	2020-02-03	Novo anticorpo anti-netrina 1
DK3191498T3 (da)	2020-12-21	Fremgangsmåde til fremstilling af 2'-o-fucosyllactose
DK3228312T3 (da)	2020-04-20	Immunregulator
DK3463001T3 (da)	2021-06-21	Kogegrej
EP3571288A4 (fr)	2020-12-02	Induction d'immunité protectrice contre des antigènes
BE1022355A1 (fr)	2016-02-16	Nouvelles méthodes d'induction d'une réponse immunitaire
MA45305A (fr)	2019-01-23	Suspension améliorée
MA49771A (fr)	2020-06-10	Induction d'une immunité protectrice contre des antigènes
EP3362578A4 (fr)	2019-03-20	Méthodes d'évaluation génomique du bétail
DK3571208T3 (da)	2021-05-10	Immunproteasominhibitorer
LT3122378T (lt)	2020-02-10	Mutantų stafilokokiniai antigenai
FI20145103L (fi)	2015-07-31	Magneetti

Legal Events

Date	Code	Title	Description
2019-12-19	MM	Lapsed because of non-payment of the annual fee	Effective date: 20190430